AbbVie faces a tough balancing act as Humira falls behind a wave of biosimilars. Once the crown jewel of pharma with billions in annual sales, Humira’s dominance is slipping, especially in the U.S. where patent protection expired this year. Now, all eyes are on two rising stars: Skyrizi and Rinvoq. The company needs them to grow fast to fill the giant gap left by the original blockbuster.
Humira's decline isn’t a surprise. In Europe, biosimilars hit years ago, and in the U.S., multiple adalimumab copies flooded the market in 2023, including interchangeable biosimilars like Cyltezo. This pushed net prices down sharply and shifted contracts, forcing AbbVie to manage a gradual revenue drop.
Now the question becomes whether Skyrizi, targeting IL-23, and Rinvoq, a selective JAK inhibitor, can expand quickly enough across multiple diseases like psoriasis, rheumatoid arthritis, and gastrointestinal conditions. AbbVie designed these drugs to capture broad autoimmune markets, layering new treatment approvals as research and regulators catch up. Their success will determine if AbbVie can keep cash flows strong despite Humira’s exit from exclusivity.
The pressure is high because once exclusivity is lost, payers re-evaluate pricing aggressively. Doctors experiment with alternatives and patients ask about cheaper options, accelerating the speed of revenue erosion. For portfolio managers tracking pharma cash flows, it’s a classic example of how a company rebuilds its core from within when a giant like Humira fades.
AbbVie's upcoming earnings call will reveal just how well these newer drugs are performing as the company tries to transition its product base.
material is informational and not financial advice
